Residual Atherosclerotic Cardiovascular Disease Risk in Statin Users: A Systematic Review and Meta‐Analysis
Journal of the American Heart Association · 01.09.2026 · 15 (17)
DOI: 10.1161/jaha.125.044840 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of the American Heart Association, erschienen am 01.09.2026. Verfasst von Alexandre H Watanabe und 8 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co, Inc Rahway NJ. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis, Cardiovascular Diseases. Die Arbeit nennt 112 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Statins are the cornerstone of lipid‐lowering therapy, reducing low‐density lipoprotein cholesterol in adults. However, residual atherosclerotic cardiovascular disease (ASCVD) risk among statin users remains unclear. This study estimated residual ASCVD risk in statin users in practice.
Methods
We conducted a systematic literature review and meta‐analyses following Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines, including observational studies published January 1, 2013, to August 1, 2023, that reported ASCVD risk in adult statin users. Five outcomes were assessed: composite risk (major adverse cardiovascular events or all‐cause death), myocardial infarction, ischemic stroke, cardiovascular‐related death, and coronary revascularization. Meta‐analysis methods were used to synthesize individual study estimates. For each outcome, forest plots present study‐level estimates and the pooled incidence rate per 1000 person‐years (PPY).
Results
The meta‐analysis of residual composite risk (major adverse cardiovascular events or all‐cause death) in the overall population was 12.3 PPY (range, 0.2–72.0). Rates were lower in adults at risk of ASCVD (6.4 PPY [range, 3.7–9.8 PPY]) and higher in adults with prior ASCVD (15.8 PPY [range, 0.2–72.0 PPY]). Meta‐analysis for myocardial infarction showed 8.23 PPY (range, 1.1–88.82 PPY) in the overall patient population, and a lower rate of ischemic stroke with a rate of 6.0 PPY (range, 1.4–18.8 PPY). A rate of 4.3 PPY (range, 0.4–22.9 PPY) was estimated for cardiovascular‐related death, and 7.4 PPY for coronary revascularization (range, 3.1–27.6 PPY).
Conclusions
Despite substantial between‐study variability, this real‐world meta‐analysis indicates meaningful residual ASCVD risk among statin users, underscoring persistent treatment gaps and need for comprehensive, optimized risk management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Merck & Co, Inc Rahway NJ.
- Lumanity Sheffield UK.
- Lumanity Utrecht the Netherlands.
- Lumanity Gurugram India.
- Section of Cardiovascular Medicine Yale School of Medicine New Haven CT.
ORCID-Profile: Alexandre H Watanabe, Lori D Bash, Tracy Westley, Andrea Garcia, Emily Aiello, Jasmine Bradbury, Michael G Nanna
Zitieren
APA
Watanabe, A. H., Bash, L. D., Westley, T., Garcia, A., Aiello, E., Bradbury, J., Garg, J., Telukuntla, V., & Nanna, M. G. (2026). Residual Atherosclerotic Cardiovascular Disease Risk in Statin Users: A Systematic Review and Meta‐Analysis. Journal of the American Heart Association, 15(17). https://doi.org/10.1161/jaha.125.044840
Vancouver
Watanabe AH, Bash LD, Westley T, Garcia A, Aiello E, Bradbury J, et al. Residual Atherosclerotic Cardiovascular Disease Risk in Statin Users: A Systematic Review and Meta‐Analysis. Journal of the American Heart Association. 2026;15(17). doi:10.1161/jaha.125.044840
BibTeX
@article{Watanabe2026,
author = {Watanabe, Alexandre H and Bash, Lori D and Westley, Tracy and Garcia, Andrea and Aiello, Emily and Bradbury, Jasmine and Garg, Jyoti and Telukuntla, Vyshnavi and Nanna, Michael G},
title = {Residual Atherosclerotic Cardiovascular Disease Risk in Statin Users: A Systematic Review and Meta‐Analysis},
journal = {Journal of the American Heart Association},
year = {2026},
volume = {15},
number = {17},
doi = {10.1161/jaha.125.044840}
}
EUVIMED